Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3919-3926

  Cloosen, Silvie ^a   Arnold, Janna ^b   Thio, Marco ^a   Bos, Gerard M J ^a   Kyewski, Bruno ^b   Germeraad, Wilfred T V ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; MUCIN 1; TUMOR ANTIGEN;

ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LUNG CARCINOMA; MULTIPLE MYELOMA; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PURIFICATION;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CHILD, PRESCHOOL; EPITHELIAL CELLS; GLYCOSYLATION; HUMANS; INFANT; INFANT, NEWBORN; MUCINS; PROTEIN ISOFORMS; SELF TOLERANCE; THYMUS GLAND;

EID: 34248550936     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2112     Document Type: Article

References (51)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5: 296-306.
2. Thumann P, Moc I, Humrich J, et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003;277:1-16.
3. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
4. van Denderen J, ten Hacken P, Berendes P, et al. Recognition of the ALL-specific BCR-ABL junction in P190bcr-abl by monoclonal antibody ER-FP1. Leukemia 1994;8:1503-9.
5. Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005;117: 596-604.
6. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004;199:155-66.
7. Derbinski J, Schulte A, Kyewski B, Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001;2:1032-9.
8. Bos R, van Duikeren S, van Hall T, et al. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 2005;65:6443-9.
9. Allen S, Read S, DiPaolo R, et al. Promiscuous thymic expression of an autoantigen gene does not result in negative selection of pathogenic T cells. J Immunol 2005; 175:5759-64.
10. Doyle HA, Mamula MJ. Posttranslational modifications of self-antigens. Ann N Y Acad Sci 2005;1050:1-9.
11. Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004;16:753-8.
12. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-65.
13. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
14. Schol DJ, Meulenbroek MF, Snijdewint FG, et al. 'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumour Biol 1998;19 Suppl 1:35-45.
15. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47: 5476-82.
16. Link T, Backstrom M, Graham R, et al. Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium. J Biotechnol 2004;110:51-62.
17. van Leeuwen EBM, Cloosen S, Senden-Gijsbers BLMG, et al. Expression of aberrantly glycosylated tumor Mucin-1 on human dendritic cells after transduction with a fiber-modified adenoviral vector. Cytotherapy 2005;8:24-35.
18. Girling A, Bartkova J, Burchell J, Gendler S, Gillett C, Taylor-Papadimitriou J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int J Cancer 1989;43:1072-6.
19. Verstijnen CP, Arends JW, Moerkerk PT, Warnaar S, Hilgers J, Bosman FT. CEA-specificity of CEA-reactive monoclonal antibodies. Immunochemical and immunocytochemical studies. Anticancer Res 1986;6: 97-104.
20. r 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;56:714-21.
21. Cloosen S, Thio M, Vanclee A, et al. Mucin-1 is expressed on dendritic cells, both in vitro and in vivo. Int Immunol 2004;16:1561-71.
22. Hale LP, Markert ML. Corticosteroids regulate epithelial cell differentiation and Hassall body formation in the human thymus. J Immunol 2004;172:617-24.
23. Kyewski B, Derbinski J. Self-representation in the thymus: an extended view. Nat Rev Immunol 2004;4: 688-98.
24. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51.
25. Reis CA, David L, Seixas M, Burchell J, Sobrinho-Simoes M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 1998;79:402-10.
26. Derbinski J, Gabler J, Brors B, et al. Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 2005;202:33-45.
27. Schmitz-Winnenthal FH, Volk C, Zgraggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65:10079-87.
28. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006;66:8258-65.
29. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-8.
30. Zehn D, Bevan MJ. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006;25:261-70.
31. Liu KJ. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004;10:2645-51.
32. Galli-Stampino L, Meinjohanns E, Frische K, et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997;57:3214-22.
33. Hanisch FG, Schwientek T, Bergwelt-Baildon MS, Schultze JL, Finn O. O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 2003;33: 3242-54.
34. Jensen T, Hansen P, Galli-Stampino L, et al. Carbohydrate and peptide specificity of MHC class II-restricted T cell hybridomas raised against an O-glycosylated self peptide. J Immunol 1997;158:3769-78.
35. Hiltbold EM. Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999;194:143-9.
36. Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 2004;20: 73-9.
37. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 1997;9:791-8.
38. Xu Y, Gendler SJ, Franco A. Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med 2004;199:707-16.
39. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143:139-49.
40. Backlund J, Carlsen S, Hoger T, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci U S A 2002;99:9960-5.
41. Nissim A, Winyard PG, Corrigall V, et al. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum 2005;52:3829-38.
42. Van den Steen PE, Proost P, Brand DD, Kang AH, van Damme J, Opdenakker G. Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B. Biochemistry 2004;43:10809-16.
43. Ng B, Yang F, Huston DP, et al. Increased non-canonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004;114:1463-70.
44. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998;58:315-21.
45. Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001;101:192-200.
46. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-63.
47. Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice. Cancer Res 2004; 64:4995-5003.
48. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006;24:571-606.
49. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988;11-12: 55-101.
50. Scholzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 2000;156:595-605.
51. Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.